This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations covering NITs, artificial intelligence and bariatric surgery at TLM2023.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations of clinical trial results at TLM 2023.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers the four panelists’ general impressions of TLM2023, both the good and bad of it.
Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green to discuss highlights of the recent TLM2023 conference.
Patient Advocate Michael Betel of the Fatty Liver Alliance joins Roger Green to discuss the presentations, events and themes of TLM 2023 he found most empowering for patients and advocates.
Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.
Previewing The Liver Meeting 2023: Last week’s posting consisted of 1:1 interviews with four KOL from different spheres, each talking with Roger Green about what they are looking forward to seeing at this week’s The Liver Meeting 2023. This week, two of those KOLs, co-host Jörn Schattenberg and hepatology KOL Naim Alkhouri, join Roger and co-host Louise Campbell, FRCP, in a free-wheeling review of key abstracts that will be presented at TLM2023.
Ken Cusi and Roger Green are joined by Diana Barb and Jay Shubrook in a discussion around effective therapies and strategies for fighting fatty liver disease that are available now. The group discusses frontline screening, medications, bariatric surgery, lifestyle management, practical insights and much more.
Jörn Schattenberg, Louise Campbell and Roger Green discuss what’s happening thus far for the Fatty Liver field in 2023. The panelists touch on topics ranging from trials with non-invasive endpoints to guidelines, guidances and cross-specialty screening for liver health.
This week, SurfingNASH.com is offering a 17-minute section of our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.” Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity.
